What Brainomix does
Brainomix makes AI-powered imaging software that automatically analyses brain and lung CT and MRI scans, including its Brainomix 360 Stroke platform for ASPECTS scoring, core-volume and large-vessel-occlusion detection, and an FDA-cleared e-Lung product. The company says its technology is deployed in over 300 hospitals across more than 20 countries and has been used in over 1.5 million patient cases. Brainomix spun out of the University of Oxford's preclinical stroke lab in 2010, founded by Michalis Papadakis. The company also partners with pharmaceutical sponsors such as Boehringer Ingelheim and AstraZeneca on clinical trial imaging.
Brainomix is a healthcare tool on Falcoscan. AI imaging software that speeds up stroke and lung diagnosis. Falcoscan rates Brainomix with an Opportunity score of 84/100, a Saturation score of 11/100, and a Wrapper-risk score of 9/100. Market signal: rising. Brainomix is founded in 2010, currently at Series_c stage. Pricing: Paid.